chufangao/CTO huggingface dataset:
Clinical trial NCT03110354: DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Official title: A Phase 1 Study of DS-3201b in Subjects With Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Sponsor: Daiichi Sankyo (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: This study was terminated due to slow accrual.
Enrollment: 28.0 (ACTUAL)
Number of arms: 5.0
Start date: 2017-04-05
Primary completion date: 2021-03-09
Completion date: 2021-03-09
Baseline population: Demographic and baseline characteristics were assessed in the Safety Analysis Set.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Clinical trial NCT03888092: Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification
Official title: A Phase Ib, Multi-center, Open-label Study of Z650 in Advanced Esophageal Squamous Cell Carcinoma (ECSS) With Epidermal Growth Factor Receptor (EGFR) Over Expression or Gene Amplification
Sponsor: Sunshine Lake Pharma Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 81.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-08-18
Primary completion date: 2022-12-13
Completion date: 2022-12-13
Plan to share individual participant data: NO
Clinical trial NCT01836068: Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals
Official title: Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1-infected Individuals
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-06-30
Primary completion date: 2020-01-22
Completion date: 2021-06-05
Plan to share individual participant data: NO
Clinical trial NCT03655613: APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
Official title: A Phase 1/2 Dose Escalation and Expansion Study of Combination APL-501 or Nivolumab With APL-101 in Locally Advanced or Metastatic Hepatocellular and Renal Cell Carcinoma
Sponsor: Apollomics (Australia) Pty. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study terminated due to administrative reasons.
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-05
Primary completion date: 2021-12-15
Completion date: 2021-12-15
Clinical trial NCT03362424: Mesenchymal Stem Cells in Rotator Cuff Repair
Official title: Mesenchymal Stem Cells in Rotator Cuff Repair - a Randomized Prospective Study
Sponsor: University of Sao Paulo (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: Cryogenesis company stopped supplying mesenchymal cells
Enrollment: 44.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2020-11-01
Primary completion date: 2023-12-01
Completion date: 2023-12-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03704298: Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma
Official title: A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma
Acronym: ZUMA-11
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Development program terminated
Enrollment: 15.0 (ACTUAL)
Number of arms: 6.0
Start date: 2018-11-20
Primary completion date: 2021-05-07
Completion date: 2022-12-15
Baseline population: The Safety Analysis Set is defined as all participants treated with any dose of axicabtagene ciloleucel.
Plan to share individual participant data: YES
IPD sharing description: Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/
IPD time frame: 18 months after study completion
IPD access criteria: A secured external environment with username, password, and RSA code.
Clinical trial NCT04120402: Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee
Official title: A Phase 2, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety, Efficacy and Pharmacokinetics of Single Dose EP-104IAR for 24 Weeks in Patients With Osteoarthritis of the Knee
Acronym: SPRINGBOARD
Sponsor: Eupraxia Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 318.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-10
Primary completion date: 2023-05-17
Completion date: 2023-06-01
Baseline population: The intention-to-treat (ITT) population consisted of all subjects who were both randomized to and received treatment. Analysis was conducted allocating subjects to the treatment to which they were randomized, irrespective of what was actually received. The safety population consisted of all randomized subjects who were administered a dose of study drug. The subjects in this group were analyzed based on the treatment they received.
Plan to share individual participant data: NO
Clinical trial NCT04458298: A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients
Official title: A Two-Stage, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OP-101 (Dendrimer N-acetyl-cysteine) in Patients With Severe COVID-19
Acronym: PRANA
Sponsor: Ashvattha Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of enrollment
Enrollment: 28.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-08-11
Primary completion date: 2022-08-12
Completion date: 2022-08-12
Plan to share individual participant data: NO
Clinical trial NCT03159988: Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients
Official title: Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients
Sponsor: University of Arizona (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: Slow enrollment
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-04-30
Primary completion date: 2022-11-15
Completion date: 2022-11-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04572776: Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain
Official title: A Multicenter, Randomized, 2-Arm, Phase 3 Study to Assess the Efficacy and Safety of a Single Epidural Administration of Resiniferatoxin Versus Standard of Care (SoC) for the Treatment of Intractable Pain Associated With Cancer
Sponsor: Sorrento Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: To be replaced by a different protocol
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-31
Primary completion date: 2023-03-31
Completion date: 2023-03-31
Clinical trial NCT03875495: A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)
Official title: A Phase I/II Dose Escalation Study Evaluating Safety and Activity of Autologous CD34+-Enriched Hematopoietic Progenitor Cells Genetically Modified With a Lentiviral Vector Encoding for the Human Interferon-ɑ2 Gene in Multiple Myeloma Patients With Early Relapse After Intensive Front Line Therapy
Sponsor: Genenta Science (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Failure to recruit patients
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-06
Primary completion date: 2021-04-02
Completion date: 2021-04-02
Baseline population: No patients completed the baseline visit
Limitations and caveats: Although 3 patients were recruited, no patients received Temferon
Plan to share individual participant data: NO
Clinical trial NCT04602117: ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
Official title: ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Sponsor: QuantumLeap Healthcare Collaborative (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-07-28
Primary completion date: 2021-11-17
Completion date: 2021-11-17
Plan to share individual participant data: NO
Clinical trial NCT02607813: Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Official title: A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Enrollment: 142.0 (ACTUAL)
Number of arms: 6.0
Start date: 2016-01-18
Primary completion date: 2022-02-18
Completion date: 2022-02-19
Plan to share individual participant data: NO
Clinical trial NCT03726879: A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
Official title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
Acronym: IMpassion050
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 454.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-11
Primary completion date: 2021-02-05
Completion date: 2023-08-24
Limitations and caveats: On February 5, 2021, the experimental treatment was discontinued and unblinded following the recommendation of the independent Data Monitoring Committee (iDMC) to stop treatment with atezolizumab/placebo.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT04608812: Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
Official title: A Pilot Study of Intratumorally and Intraparenchymally Administered OS2966 Using Convection-enhanced Delivery in Patients With Recurrent/Progressive High-grade Glioma Undergoing a Clinically-indicated Surgical Resection
Sponsor: OncoSynergy, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Slow enrollment and financial constraints.
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-02
Primary completion date: 2023-02-27
Completion date: 2023-02-27
Clinical trial NCT04058197: Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment
Official title: A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Efficacy of Deferoxamine Intradermal Delivery Patch (DIDP) in Chronic Sickle Cell Leg Ulcers
Acronym: D-SCOUT
Sponsor: TauTona Group (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Lack of enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-21
Primary completion date: 2021-10-06
Completion date: 2021-10-06
Clinical trial NCT03851263: Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion
Official title: Multi-slice CT Scan Assessment of the Impact of PCSK9 Inhibition With Evolocumab on Coronary Perfusion in Patients With Reduced Coronary Fractional Flow Reserve (FFR).
Acronym: MARKOV
Sponsor: ECRI bv (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Admisnitrative issues
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-30
Primary completion date: 2021-08-27
Completion date: 2023-02-24
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03896945: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Based on the Interim Analysis outcome and recommendation by the DMC, Otsuka approved termination of the study based on futility.
Enrollment: 136.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-15
Primary completion date: 2023-05-23
Completion date: 2023-05-23
Plan to share individual participant data: YES
IPD sharing description: Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
IPD time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
IPD access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Clinical trial NCT04424225: Visual Surround Suppression and Perceptual Expectation Under Psilocybin
Official title: Visual Surround Suppression and Perceptual Expectation Under Psilocybin
Sponsor: University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Could not secure additional funding to continue the study. Pilot phase of study completed.
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-30
Primary completion date: 2023-09-01
Completion date: 2023-09-01
Plan to share individual participant data: YES
IPD sharing description: For data releases, requests for sharing will be made to the PI, Jessica Nielson or the student investigator, Link Swanson, and/or co-investigators Michael-Paul Schallmo, Kathryn Cullen, or Ranji Varghese and granted on an individual basis
Clinical trial NCT02781506: Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
Official title: Phase II Trial of Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC)
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Since the treatment landscape for metastatic kidney cancer changed, patients were not becoming eligible for this trial and therefore, the trial was terminated.
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-06-20
Primary completion date: 2021-05-24
Completion date: 2021-05-24
Plan to share individual participant data: NO
Clinical trial NCT04057573: Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
Official title: Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 344.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-10-03
Primary completion date: 2021-03-15
Completion date: 2021-10-01
Baseline population: Baseline data are reported for members of the Safety Population, comprised of all participants who applied ruxolitinib cream or vehicle cream at least once. Treatment groups for this population were determined according to the actual treatment the participant applied on Day 1.
Limitations and caveats: Data from participants at a single site were excluded from all efficacy analyses done on the Intent-to-Treat Population owing to serious noncompliance with the protocol resulting in serious concerns with the data quality.
Plan to share individual participant data: NO
Clinical trial NCT02864368: Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
Official title: Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
Acronym: PERFORMANCE
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Funding
Enrollment: 27.0 (ACTUAL)
Number of arms: 5.0
Start date: 2016-12-07
Primary completion date: 2020-06-15
Completion date: 2020-06-15
Clinical trial NCT04036968: Enhancing Medication-based Analgesia in Humans- STUDY 2
Official title: Evaluating Cannabidiol (CBD) to Enhance the Analgesic Effect of Hydromorphone in Humans
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 31.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-02-01
Primary completion date: 2022-11-01
Completion date: 2022-11-01
Plan to share individual participant data: NO
Clinical trial NCT05133323: A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
Official title: Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lu AG09222 for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments
Sponsor: H. Lundbeck A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 237.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-11-11
Primary completion date: 2023-01-19
Completion date: 2023-03-16
Baseline population: The all-participants-treated set (APTS) represents all randomized participants who received an infusion of investigational medicinal product
Clinical trial NCT02451423: Neoadjuvant Atezolizumab in Localized Bladder Cancer
Official title: Phase II Study of Neoadjuvant Atezolizumab-based Immunotherapy for Patients With Urothelial Carcinoma (NEBULA)
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 23.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-03-29
Primary completion date: 2023-03-31
Completion date: 2023-03-31
Plan to share individual participant data: NO
Clinical trial NCT03138083: OMO-1 in Solid Malignancies
Official title: A Modular, Multi-arm, Multi-part, First Time in Patient Study to Evaluate the Safety and Tolerability of OMO-1, Alone and in Combination With Anti-cancer Treatments, in Patients With Locally Advanced, Unresectable or Metastatic Solid Malignancies
Sponsor: Octimet Oncology N.V. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: strategic reasons (not due to lack of efficacy or safety issues)
Enrollment: 40.0 (ACTUAL)
Number of arms: 6.0
Start date: 2017-08-08
Primary completion date: 2020-05-25
Completion date: 2020-05-25
Plan to share individual participant data: NO
Clinical trial NCT02200614: Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
Official title: A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
Acronym: ARAMIS
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1509.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-09-12
Primary completion date: 2018-09-03
Completion date: 2021-06-14
Clinical trial NCT03318952: Articaine vs Lidocaine for Pediatric Dental Procedures
Official title: Efficacy of Articaine vs. Lidocaine When Used for Local Infiltration in Pediatric Dental Procedures
Sponsor: Boston University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: The research did not start and the PI transitioned to another institution.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-09-30
Primary completion date: 2023-06-30
Completion date: 2023-06-30
Plan to share individual participant data: NO
Clinical trial NCT03773055: Phase II Clinical Trial of NPC-06 in Patients With Neuropathic Pain in Cancer
Official title: A Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Group Trial to Investigate the Proof of Concept of NPC-06 in Patients With Neuropathic Pain in Cancer
Sponsor: Nobelpharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low recruitment
Enrollment: 7.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-04-03
Primary completion date: 2020-09-30
Completion date: 2020-09-30
Plan to share individual participant data: NO
Clinical trial NCT04917692: Empagliflozin in Adolescent Diabetes
Official title: Empagliflozin in Adolescent Diabetes
Sponsor: Ohio State University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Not funded
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-07-31
Primary completion date: 2022-06-30
Completion date: 2022-10-31
Plan to share individual participant data: NO